- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04469569
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors Receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). Compared with the age- and sex-matched general population, female and male cancer survivors have a 1.4- to 2.5-fold excess risk, respectively, of developing HPV-related malignancies. Fortunately, HPV-related malignancies are largely preventable due to availability of the nonavalent HPV vaccine, which offers protection against ~90% of oncogenic HPV subtypes. We have previously shown that uptake of the HPV vaccine is significantly lower in cancer survivors compared with general population peers (22.0% vs 42.5% in those age 13-17yrs), and that lack of healthcare provider recommendation is the strongest predictor of HPV vaccine non-initiation in cancer survivors. Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on improving healthcare provider knowledge about the HPV vaccine, enhancing the skills that healthcare providers need to effectively recommend the vaccine to young people and their parents, and reducing barriers to receiving the vaccine.
This study will evaluate the effectiveness and implementation of an evidence-based intervention (HPV-PROTECT), adapted for use by healthcare providers in pediatric oncology clinics, to increase the uptake of HPV vaccine among young cancer survivors (9 to 17 years of age and at least one year following completion of cancer therapy). The HPV-PROTECT intervention has three components: i) Provider Communication Training; ii) Assessment and Peer Feedback/Coaching; and iii) Provider Toolkit, and is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans. If the intervention is effective in improving and sustaining increased uptake of the HPV vaccine in young cancer survivors, this study will contribute important information needed to move forward with testing the widespread use of the intervention in pediatric oncology practices.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wendy Landier, PhD
- Phone Number: 205-638-2120
- Email: wclandier@uabmc.edu
Study Contact Backup
- Name: Lindsey Hageman, MPH
- Phone Number: 205-638-2120
- Email: lihageman@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Wendy Landier, PhD
- Phone Number: 205-638-2120
- Email: wclandier@uabmc.edu
-
Contact:
- Lindsey Hageman, MPH
- Phone Number: 205-638-2120
- Email: lihageman@uabmc.edu
-
Principal Investigator:
- Wendy Landier, PhD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- James L Klosky, PhD
- Phone Number: 404-712-5791
- Email: james.klosky@emory.edu
-
Principal Investigator:
- James L Klosky, PhD
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455-0341
- Recruiting
- University of Minnesota
-
Contact:
- Lucie Turcotte, MD, MPH, MS
- Email: turc0023@umn.edu
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157-0001
- Recruiting
- Wake Forest University Health Sciences
-
Contact:
- Thomas McLean, MD
- Email: tmclean@wakehealth.edu
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Recruiting
- Oregon Health and Science University
-
Contact:
- Susan Lindemulder, MD
- Email: lindemul@ohsu.edu
-
-
Texas
-
Houston, Texas, United States, 77030-3411
- Recruiting
- Baylor College of Medicine
-
Contact:
- Maria M Gramatges, MD, PhD
- Email: gramatge@bcm.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
HEALTHCARE PROVIDERS (ONCOLOGISTS, ADVANCED PRACTICE PROVIDERS)
- ≥18y of age
- Care for cancer survivors seen in the targeted clinic who are age 9-17y, ≥1y off-therapy, and reside in the state where clinic is located
- Licensed to order vaccines
- Willing to complete surveys and/or interviews
CHILDHOOD CANCER SURVIVORS
- 9-17y of age
- ≥1y following completion of cancer therapy
- Reside in the state where clinic is located
- Receive follow-up care (in person or via telehealth) at the participating sites
Exclusion Criteria:
N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Delayed Intervention
Sites randomized to the Delayed Intervention Arm (Sites A, B, C) will be assigned to the control condition in Years 1 and 2, to the HPV-PROTECT intervention in Year 3, and to the sustainability condition in Year 4
|
HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues.
The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit.
The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
|
Other: Early Intervention
Sites randomized to the Early Intervention Arm (Sites D, E, F) will be assigned to the control condition in Year 1, to the HPV-PROTECT intervention in Year 2, and to the sustainability condition in Years 3 and 4
|
HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues.
The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit.
The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccine initiation rates
Time Frame: 12 months following implementation of the HPV-PROTECT Intervention.
|
Proportion of cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit (in-person or via telehealth) at one of the participating sites during the intervention year, and who have initiated the HPV vaccine series, as measured via state vaccine registry data
|
12 months following implementation of the HPV-PROTECT Intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Provider perspectives regarding intervention feasibility, acceptability, appropriateness, fidelity
Time Frame: Months 11-12 of the Intervention Year (i.e., Year 2 for sites D, E, F and Year 3 for sites A, B, C)]
|
Descriptive statistics summarizing provider survey data and qualitatively coded provider interview data integrated to evaluate the feasibility (perceived potential for success), acceptability (perceived need), and appropriateness (perceived fit) of the HPV-PROTECT intervention to the pediatric oncology setting, and provider adherence (fidelity) to intervention components (e.g., delivery of recommendations, developing and communicating vaccine action plans to parents and PCPs)
|
Months 11-12 of the Intervention Year (i.e., Year 2 for sites D, E, F and Year 3 for sites A, B, C)]
|
Change in provider HPV vaccine-related knowledge and practices
Time Frame: 12 and 24 months [all sites], and 36 months [sites D, E, F only] following implementation of the HPV-PROTECT Intervention)
|
Descriptive statistics summarizing provider HPV vaccine-related knowledge and practices as reported on provider surveys
|
12 and 24 months [all sites], and 36 months [sites D, E, F only] following implementation of the HPV-PROTECT Intervention)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccine series completion rates
Time Frame: 12 and 24 months (all sites), and 36 months (sites D, E, F only) following implementation of the HPV-PROTECT Intervention
|
Proportion of cancer survivors, age 9-17y, and ≥1y post-completion of cancer therapy, who completed a clinic visit (in-person or via telehealth) at one of the participating sites during the intervention or sustainability years, and who have completed the HPV vaccine series, as measured via state vaccine registry data
|
12 and 24 months (all sites), and 36 months (sites D, E, F only) following implementation of the HPV-PROTECT Intervention
|
Sustainability of HPV vaccine initiation rates
Time Frame: 24 months (all sites) and 36 months (sites D, E, F only) following implementation of the HPV-PROTECT Intervention
|
Proportion of cancer survivors, age 9-17y and ≥1y post-completion of cancer therapy, who completed a clinic visit (in person or via telehealth) at one of the participating sites during the intervention and/or sustainability years, and who have initiated the HPV vaccine series, as measured via state vaccine registry data
|
24 months (all sites) and 36 months (sites D, E, F only) following implementation of the HPV-PROTECT Intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Wendy Landier, PhD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRB-300005305
- 1U01CA246567-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillomavirus Vaccines
-
Huong McLean, PhDCenters for Disease Control and PreventionActive, not recruitingPapillomavirus VaccinesUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus VaccinesUnited States
-
Arizona State UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Adelante...Completed
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI); Southern Methodist University; Parkland Health...TerminatedHuman Papillomavirus VaccinesUnited States
-
Laval UniversityCenters for Disease Control and PreventionCompletedHuman Papillomavirus VaccinesCanada
-
University of CincinnatiRecruitingPapillomavirus Vaccines | Human Papillomavirus VirusesUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Not yet recruitingHuman Papillomavirus Vaccines
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI); Southern Methodist University; Parkland Health...CompletedHuman Papillomavirus VaccinesUnited States
-
GlaxoSmithKlineCompletedInfections, Papillomavirus | Papillomavirus VaccinesBelgium, United States
-
GlaxoSmithKlineCompletedInfections, Papillomavirus | Papillomavirus VaccinesDenmark, Poland, Lithuania
Clinical Trials on HPV-PROTECT
-
Lungpacer Medical Inc.CompletedAcute Respiratory Distress Syndrome | Ventilation Therapy; ComplicationsFrance
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); New York City Department for the...RecruitingDepression | Elder AbuseUnited States
-
Pädagogische Hochschule HeidelbergHeidelberg UniversityUnknown
-
Weill Medical College of Cornell UniversityThe Fan Fox & Leslie R. Samuels Foundation, Inc.; New York City Department... and other collaboratorsCompleted
-
Lund UniversityTerminated
-
LiveLeaf Inc.UnknownAntibiotic-associated Diarrhea
-
Lund UniversityActive, not recruitingAthletic Injuries | Health BehaviorSweden
-
University of MiamiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPregnancy | HIVSouth Africa
-
Pädagogische Hochschule HeidelbergDietmar Hopp StiftungUnknownMental Disorders